Multicentric occurrence of hepatocellular carcinoma with nonalcoholic steatohepatitis

Hirokazu Kawai, Minoru Nomoto, Takeshi Suda, Kenya Kamimura, Atsunori Tsuchiya, Yasushi Tamura, Masahiko Yano, Masaaki Takamura, Masato Igarashi, Toshifumi Wakai, Satoshi Yamagiwa, Yasunobu Matsuda, Shogo Ohkoshi, Isao Kurosaki, Yoshio Shirai, Masahiko Okada, Yutaka Aoyagi

HIROKAZU KAWAI, Department of Clinical Laboratory, Niigata University Medical and Dental Hospital, Niigata 951-8510, Japan
MINORU NOMOTO, TAKESHI SUDA, KENYA KAMIMURA, ATSUNORI TSUCHIYA, YASUSHI TAMURA, MASAHIKO YANO, MASAAKI TAKAMURA, MASATO IGARASHI, SATOSHI YAMAGIWA, SHOGO OKOSHI, YUTACA AOYAGI, Division of Gastroenterology and Hepatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan
TOSHIFUMI WAKAI, ISAO KUROSAKI, YOSHI SHIRAI, Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan
YASUNOBU MATSUDA, Department of Medical Technology, Niigata University Graduate School of Health Sciences, Niigata 951-8518, Japan
MASAHIKO OKADA, Division of Preventive Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan

Author contributions: Kawai H is a physician who drafted the manuscript and revised critically for content; Nomoto M contributed to the pathological analysis; Suda T was a major contributor to writing the manuscript; Kamimura K, Tsuchiya A, Tamura Y, Yano M, Takamura M, Igarashi M, Yamagiwa S, Matsuda Y, Ohkoshi S and Aoyagi Y are physicians who have treated the patients and analyzed the data; Wakai T, Kurosaki I and Shirai Y are surgeons who treated the patients; and Okada M contributed to the analysis of the data.

Correspondence to: Hirokazu Kawai, MD, PhD, Department of Clinical Laboratory, Niigata University Medical and Dental Hospital, 1-757 Asahimachi-dori Chuo-ku, Niigata 951-8510, Japan. kawaih@med.niigata-u.ac.jp
Telephone: +81-25-2272336 Fax: +81-25-2230996
Received: September 3, 2010 Revised: November 11, 2010
Accepted: November 18, 2010
Published online: January 27, 2011

Abstract

AIM: To reveal the manner of hepatocellular carcinoma (HCC) development in patients with nonalcoholic steatohepatitis (NASH) focusing on multicentric occurrence (MO) of HCC.

METHODS: We compared clinicopathological characteristics between patients with and without MO of HCC arising from NASH background. The clinical features were implicated with reference to the literature available.

RESULTS: MO of HCC was identified with histological proof in 4 out of 12 patients with NASH-related HCC (2 males and 2 females). One patient had synchronous MO; an advanced HCC, two well-differentiated HCCs and a dysplastic nodule, followed by the development of metachronous MO of HCC. The other three patients had multiple advanced HCCs accompanied by a well-differentiated HCC or a dysplastic nodule. Of these three patients, one had synchronous MO, one had metachronous MO and the other had both synchronous and metachronous MO. There were no obvious differences between the patients with or without MO in terms of liver function tests, tumor markers and anatomical extent of HCC. On the other hand, all four patients with MO of HCC were older than 70 years old and had the comorbidities of obesity, type 2 diabetes mellitus (T2DM), hypertension and cirrhosis. Although these conditions were not limited to MO of HCC, all the conditions were met in only one of eight patients without MO of HCC. Thus, concurrence of these conditions may be a predisposing situation to synchronous MO of HCC. In particular, old age, T2DM and cirrhosis were suggested to be prerequisite for MO because these factors were depicted in common among two other cases with MO of HCC under NASH in the literature.

CONCLUSION: The putative predisposing factors and necessary preconditions for synchronous MO of HCC in NASH were suggested in this study. Further investigations are required to clarify the accurate prevalence and predictors of MO to establish better strategies for treatment and prevention leading to the prognostic improvement in NASH.
INTRODUCTION

With the increasing prevalence of obesity and type 2 diabetes mellitus (T2DM), nonalcoholic fatty liver disease (NAFLD) has become pandemic, particularly in developed countries, causing public health problems. Within the broad spectrum of the pathophysiology of NAFLD, nonalcoholic steatohepatitis (NASH) is the most serious form because of its propensity to progress toward a fatal event. Although NASH was previously thought to be often indolent[3-7], the following analyses revealed that NASH leads to fibrosis of the liver, cirrhosis and eventually hepatocellular carcinoma (HCC) in a substantial number of patients[8-13]. HCC is currently regarded as a late complication of NASH according to a number of recent reports[3,7]. In addition, it was recently shown that the development of HCC is associated with mortality in cirrhotic NASH in a prospective study in Japanese cohort[3]. Thus, it is very important to elucidate the natural course of NASH in terms of the development of HCC for better management.

Multicentric occurrence (MO) and intrahepatic metastasis (IM) are characteristic in the development of HCC with chronic liver diseases that are caused by hepatitis B virus (HBV) or hepatitis C virus (HCV) [8-13]. It is very important to distinguish MO from IM so that appropriate treatment options may be selected in a variety of clinical settings. Unfortunately, there have been few studies that focus on the characterization of MO in NASH-related HCC despite the increasing number of case reports on HCC based on NASH.

In this report, characteristic features of NASH cases that developed HCC with MO are discussed.

MATERIALS AND METHODS

Patients

From July 2002 to March 2010, we diagnosed and treated 40 adult patients with NASH at the Division of Gastroenterology and Hepatology, Niigata University Medical and Dental Hospital. Of these, HCC was observed in 12 cases including 4 with MO of HCC. The proportion of HCC patients is high in our series with NASH because our hospital is a tertiary referral center and most of the NASH patients who are referred to us are complicated cases.

Definitions

NASH was defined to satisfy all of the following requirements: (1) an absence of clinically significant alcohol intake (less than 20 g/d of ethanol consumption); (2) histological features showing steatosis with various combinations of ballooning liver cells, inflammatory infiltrate of neutrophils, pericellular fibrosis and Mallory bodies; and (3) no other liver diseases. All non-tumorous specimens were histologically scored according to the classification by Brunt et al[8].

MO of HCC was pathologically determined according to the classification of the Liver Cancer Study Group of Japan[13] as follows: 2 or more separate lesions including an early HCC with a dysplastic nodule or no substantial destruction of the preexisting hepatic framework, or moderately and/or poorly differentiated HCCs with a margin of well-differentiated HCC. When histological specimens of HCC could not be obtained, MO was identified by particular findings that correspond to MO on imaging studies[10,17].

Advanced HCCs were defined when they had a vascular pattern that was consistent with contrast enhancement in the arterial phase followed by rapid washout in the portal and/or equilibrium phases on dynamic computed tomography (CT) and/or dynamic magnetic resonance (MR) imaging. A nodule was also diagnosed with an advanced HCC when the lesion was depicted as a defect on CT during arterial portography (CTAP) and as a hyperattenuated lesion in the first phase of double-phase CT during hepatic arteriography (CTHA) followed by coronary enhancement in the second phase[14,15,17]. A nodule-in-nodule appearance on dynamic CT, dynamic MR imaging or CTHA was regarded as a specific finding that indicated the emergence of a dedifferentiated component (moderately or poorly differentiated HCC) within a well-differentiated HCC, even without histological proof. Otherwise, well-differentiated HCCs or dysplastic nodules were diagnosed based on histological examinations.

The clinical stage of HCC was stratified according to the TNM classification of the Liver Cancer Study Group of Japan[18].

Obesity was defined as body mass index (BMI) ≥ 25 kg/m² according to the criteria proposed by the Japan Society for the Study of Obesity[19]. The definition was based on the fact that obesity-related diseases increase with BMI ≥ 25 kg/m² in the Japanese population. T2DM was diagnosed according to the criteria advocated by the Japan Diabetes Society as follows: fasting plasma glucose ≥ 126 mg/dL, random plasma glucose ≥ 200 mg/dL.
Table 1  Clinical characteristics of patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma with or without multicentric occurrence

| Case | HCC with MO | HCC without MO |
|------|-------------|----------------|
| Age at Dx of NASH | 73 | 81 |
| Gender | 71 | 75 |
| History of BTF | M | F |
| BMI (kg/m²) | 31.0 | 32.0 |
| T2DM | + | - |
| Hypertension | + | + |
| Dyslipidemia | + | + |
| Varices | + | + |
| Astites | + | + |
| AST (IU/L) | 91 | 67 |
| ALT (IU/L) | 46 | 49 |
| γ-GTP (IU/L) | 122 | 129 |
| Total bilirubin (mg/dL) | 1.0 | 0.7 |
| Albumin (g/dL) | 3.8 | 3.7 |
| Prothrombin time (%) | 53 | 72 |
| Platelet (x 10¹⁰/µL) | 21.1 | 12.3 |
| Child-Pugh score | A | A |
| HBsAg | + | - |
| Anti-Hbc | + | - |
| HCC | - | - |
| Dyslipidemia | + | + |
| Hypertension | + | + |
| Type of cirrhosis | Mixed | Macro |
| AFp (ng/mL) | 11 | 26 |
| DCP (mAU/mL) | 18 | 24 |
| Maximum size of HCC (mm) | 35 | 50 |
| Number of HCC | Mul | Mul |
| TNM stage | III | III |
| Initial treatment | Ope | TACE |
| Outcome | Alive | Dead |
| Cause of death | LR | NLR |

HCC: hepatocellular carcinoma; MO: multicentric occurrence; Dx: diagnosis; BTF: blood transfusion; BMI: body mass index; M: Male; F: Female; T2DM: type 2 diabetes mellitus; AST: aspartate aminotransferase; ALT: alanine aminotransferase; γ-GTP: γ-glutamyltranspeptidase; NA: not available; AFp: alpha-fetoprotein; DCP: des-γ-carboxy-prothrombin; Mixed: mixed nodular cirrhosis; Macro: macronodular cirrhosis; Mul: multiple; Sol: solitary; TACE: transcatheter arterial chemoembolization; TAI: transcatheter arterial infusion chemotherapy; RFA: radiofrequency ablation; Ope: operation; LR: liver-related death; NLR: non-liver-related death; †An oral administration of warfarin prevented the evaluation.

RESULTS

The clinical and laboratory data from 12 patients with NASH-related HCC are shown in Table 1. Of these, MO of HCC was observed in cases 1 to 4. Regarding common characteristics, all 4 patients with MO were over 70 years old, obese and had T2DM, hypertension and cirrhosis. Although these conditions were not limited to MO of HCC, all the conditions were met in only one (case 9) of eight patients without MO of HCC. There were no obvious differences between the patients with or without MO in terms of liver function tests, tumor markers and stages of tumor development. Although a few patients had positive anti-HBc, the titer of the antibody was low and no attribution of HBV infection to background liver disease was histologically ascertained.

The clinical courses of the 4 patients with MO of HCC are detailed below.
**Case 1**

A 73 year old female had been diagnosed with hypertension at age 40 and T2DM at age 70. After the diagnoses, she was treated with an angiotensin II receptor blocker and an oral anti-hyperglycemic agent at our affiliated hospital. A liver tumor measuring 35 mm in diameter in segment 6 was found with a nodule-in-nodule appearance on a surveillance dynamic CT in January 2003. The finding was consistently shown on dynamic MR imaging, CTAP and CTHA. Near the tumor, another nodule 8 mm in diameter was depicted as a hyperechoic nodule on ultrasonography (US) and as a perfusion defect on CTAP without early enhancement on CTHA. A well-differentiated HCC or a dysplastic nodule was suspected. The patient was referred to our hospital and underwent surgical resection of segment 6. During the operation, multiple hyperechoic nodules measuring less than 10 mm in diameter in addition to the main tumor were detected in segment 6 and segment 8 by intraoperative US which led to an additional resection of segment 8. The largest tumor in segment 6 was histologically diagnosed with a moderately differentiated HCC (Figure 1A). In addition, two well-differentiated HCCs and one dysplastic nodule were observed among the other small nodules (Figure 1B, C and D). All of these tumors were considered to occur in a multicentric manner.

In October 2008, recurrence of HCC was found in segment 8 on dynamic CT with early enhancement and the patient underwent transcatheter arterial embolization. In March 2009, one and two nodules were detected in segments 8 and 3, respectively, as hypovascular tumors measuring less than 15 mm in diameter on dynamic MR imaging that were suspicious for well-differentiated HCCs or dysplastic nodules. The tumors subsequently increased in diameter and were compatible with well-differentiated HCCs on imaging studies which suggested metachronous MO. The patient was treated with percutaneous ablation therapy and has had no recurrence of HCC after the therapy.

**Case 2**

An 81 year old male had been diagnosed with hypertension at age 40 and T2DM at age 75. After the diagnoses, he was treated with a calcium channel blocker and an oral anti-hyperglycemic agent. When he was admitted to the Division of Dermatology at our hospital for the treatment of psoriasis vulgaris, dynamic CT and MR imaging depicted multiple tumors in the bilateral lobes of the liver. The classical pattern of contrast enhancement that indicated advanced HCCs was observed in those tumors with the exception of a nodule measuring 10 mm in diameter in segment 3. This distinct nodule was recognized as hypoattenuation in the arterial and equilibrium phases on dynamic CT. Dynamic MR imaging demonstrated hypointensity only in the equilibrium phase but isointensity in the arterial phase and other sequences. The nodule was also shown as isoattenuation on CTAP and CTHA. We regarded this nodule as an equivocal lesion and decided to follow it closely. The combination therapy with transcatheter arterial infusion chemotherapy and percutaneous radiofrequency ablation was repeated four times for the advanced HCCs. Approximately 1 year later, the follow-up study with dynamic MR imaging showed an altered appearance of the nodule in segment 3; it was hypointense in the arterial and equilibrium phases and on T1- and T2-weighted images (WIs) and was slightly...
enlarged, 18 mm in diameter. This nodule was finally diagnosed with a well-differentiated HCC by tumor biopsy and the surrounding nontumorous parenchyma was histologically defined as cirrhosis derived from NASH. Thus, the development of this well-differentiated HCC was considered MO and the tumor was treated with local ablation therapy. Afterward, multiple HCCs recurred via intrahepatic metastases and transcatheter arterial chemoembolization therapies were repeated. Unfortunately, the patient died of hepatic failure with marked extension of HCCs at age 86.

Case 3
A 78 year old male was referred to our hospital for further workup and treatment of liver tumors detected on CT. Abnormal liver function tests had been found for 8 years. The patient had a 2 year history of treatment for hypertension and T2DM with oral drugs. Two tumors, 40 mm in diameter in the posterior segment and 20 mm in diameter in segment 8, respectively, were discovered on US, performed as part of the regular screening. Other imaging studies, including dynamic CT, MR imaging, CTAP and CTHA, indicated advanced HCCs. Other than those tumors, a nodule measuring 8 mm in diameter with different characteristics was detected in segment 5. The nodule was slightly hypointense in the arterial and equilibrium phases and isointense on T1- and T2-WIs of dynamic MR imaging. It was exhibited as isoattenuation on CTAP and hypointenation in both phases of CTHA. On the basis of these results, the tumor was suspicious for a well-differentiated HCC or a dysplastic nodule. The patient underwent surgical resection of the right hepatic lobe. The histological examination revealed cirrhosis of a nontumorous liver caused by NASH. The advanced tumors in the posterior segment and segment 8 were diagnosed with moderately differentiated HCCs and the distinct nodule in segment 5 was confirmed as a well-differentiated HCC which implied MO. After the surgery, the patient suffered from pneumonia, renal insufficiency and subsequent hepatic failure and he finally died of multiple organ failure approximately 2 mo later.

Case 4
A 71 year old female had received medical treatment for hypertension, dyslipidemia and T2DM at a clinic 7 years prior to presentation. At age 66, abnormal liver function tests were revealed on a routine examination and the patient was diagnosed with cryptogenic cirrhosis by liver biopsy at another hospital. Multiple liver tumors were detected on periodic US and the patient was referred to our hospital for further management. The definitive diagnosis of NASH was made as the cause of cirrhosis by a pathologist at our hospital with reevaluation of the previously obtained liver specimen. Two tumors in segment 8 and one tumor in segment 3, both less than 30 mm in diameter, were demonstrated as advanced HCCs on dynamic CT, MR imaging and CTHA. CTAP was not informative because of insufficient portal perfusion due to hepatofugal portal flow through a gastrorenal shunt. Meanwhile, a nodule in segment 1 with a diameter of 28 mm was shown as a nodule-in-nodule appearance on dynamic MR imaging. Therefore, this tumor was considered multicentric in origin. The patient was treated with transcatheter arterial chemoembolization and/or percutaneous ablation therapy. Furthermore, 18 mo after the treatment, another well-differentiated histologically confirmed HCC emerged in segment 7 and was treated with RFA. Thereafter, the patient remains alive without recurrence of HCC.

DISCUSSION
HCC occurs frequently through multicentric carcinogenesis in chronic liver diseases caused by HBV or HCV infection. In the present study, we found the prevalent occurrence of HCC with multicentric manner in patients with NASH as well. According to the previous studies based on pathological examinations, frequencies of synchronous MO in patients with HBV- or HCV-related HCC were 3.7%–16.5% and 11.9%–34.1%, respectively.[8–13] As for metachronous MO, it was reported that the 1 year, 3 year and 5 year MO rates were also as high as 5.3%, 28.9% and 50.8%, respectively, in HCC patients, most of whom were associated with HCV infection.[9] HCV infection that causes persistent active inflammation in the liver is believed to be one of the most important factors for MO of HCC.[8–13] Contrary to the abundant clinical data on MO in HBV- and HCV-related HCC, there is no epidemiological study addressing MO in NASH-related HCC. However, informative observations were reported by Oikawa et al.[25] They evaluated the liver specimens surgically obtained from 94 cases with nonB-nonC HCC and detected synchronous MO of HCC in 12 cases (12.8%). They speculated that these cases might have occult HBV infection or other undefined hepatitis virus infection. Although the etiology of the underlying chronic liver disease in this group could not be further estimated because of the lack of clinical profiles and histological findings of noncancerous liver tissues, it is not difficult to suppose a causal attribution to NASH in some cases. In addition, Tokushige et al.[35] revealed a high recurrence rate of HCC with NASH after two years or more of curative treatment. Those recurrent tumors in the later follow-up years were found in 9 of 16 patients (56.3%) and some of them were presumed to be of multicentric origin. Therefore, even in our cases without synchronous MO of HCC, it is possible that HCC may develop metachronously in the future. MO may be a frequent manner of HCC development in NASH as well and it is crucial to clarify the exact prevalence of MO with further studies.

Clinical features of patients with MO of HCC related to NASH are also quite obscure. There are only two case reports that have documented MO of HCC in NASH with histological proof. Zen et al.[36] reported a 72 year old female with HCC arising multicentrically from cirrhotic NASH. The patient was diagnosed with T2DM. Three tumors developed synchronously and metachronously and were histologically defined as a moderately differentiated HCC, a well-differentiated HCC and a
In the present report, the clinical profiles of old age, obesity, T2DM, hypertension and cirrhosis perhaps to independent factors, a concurrence of the factors of cinogenesis and insulin-like growth factor 1 might be involved in carcinogenesis.

It is unclear whether the same conditions can be respectively. Thus, it is appropriate to consider that those conditions (old age, T2DM and cirrhosis) are necessary preconditions of synchronous MO.

The role of each factor in the pathogenesis of MO of HCC is not understood. Old age and cirrhosis have been shown to be the strongest risk factors for the development of HCC in NASH with a prospective cohort study\[37\]. Obesity has been confirmed as an independent risk factor for the development of HCC in several studies\[38­42\], as has T2DM\[43­45\]. With regard to the association of T2DM, it was postulated that chronic hyperinsulinemia and insulin-like growth factor 1 might be involved in carcinogenesis\[46\]. Although MO of HCC may be attributable to independent factors, a concurrence of the factors of old age, metabolic abnormalities and cirrhosis perhaps significantly raises the malignant potential in the liver and probability of subsequent synchronous and multifocal development of HCCs. The exact mechanism of MO of HCC under those conditions needs to be elucidated.

### Table 2 Clinical characteristics of patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma with multicentric occurrence in previous and present reports

| Author         | Cases | Age older than 70 yr | Gender | Metabolic diseases | Histological features |
|----------------|-------|----------------------|--------|-------------------|-----------------------|
|                |       |                      |        |                   |                       |
|                | 1     | 1                    | 0      | 1                 | 1                     |
|                | 1     | 1                    | 0      | 1                 | 1                     |
|                | 4     | 4                    | 2      | 2                 | 4                     |
|                | 6     | 6                    | 2      | 4                 | 5                     |
| (%)           | -     | (100)                | (33.3) | (66.7)            | (83.3)                |

M: male; F: female; OB: obesity; DM: type 2 diabetes mellitus; DL: dyslipidemia; HT: hypertension; LC: liver cirrhosis; Non-LC: non-liver cirrhosis. All values represent number of cases.

### Table 3 Clinical characteristics of patients with solitary hepatocellular carcinoma related to nonalcoholic steatohepatitis in previous and present reports

| Author         | Cases | Age older than 70 yr | Gender | Metabolic diseases | Histological features |
|----------------|-------|----------------------|--------|-------------------|-----------------------|
|                |       |                      |        |                   |                       |
| Cotrim et al\[3\] | 1     | 0                    | 1      | 1                 | 1                     |
| Orikasa et al\[3\] | 1     | 0                    | 0      | 1                 | 1                     |
| Shimada et al\[3\] | 4     | 1                    | 2      | 2                 | 3                     |
| Mori et al\[3\] | 1     | 1                    | 1      | 1                 | 1                     |
| Bullock et al\[3\] | 2     | 1                    | 2      | 2                 | 2                     |
| Cuadrado et al\[3\] | 2     | 1                    | 2      | 2                 | 2                     |
| Sato et al\[3\] | 1     | 0                    | 1      | 0                 | 1                     |
| Ichikawa et al\[3\] | 2     | 0                    | 1      | 1                 | 0                     |
| Ikeda et al\[3\] | 1     | 0                    | 1      | 1                 | 0                     |
| Hai et al\[3\] | 2     | 1                    | 2      | 2                 | 2                     |
| Hashizume et al\[3\] | 7     | 5                    | 4      | 3                 | 5                     |
| Maeda et al\[3\] | 3     | 0                    | 2      | 1                 | NA                    |
| Kawada et al\[3\] | 6     | 4                    | 3      | 3                 | 2                     |
| Malik et al\[3\] | 8     | 2                    | 6      | 2                 | 5                     |
| Chagas et al\[3\] | 4     | 3                    | 3      | 2                 | 4                     |
| Takuma et al\[3\] | 8     | 5                    | 4      | 4                 | 4                     |
| Present authors | 3     | 2                    | 1      | 2                 | 2                     |
| Total          | 56    | 26                   | 35     | 21                | 36                    |
| (%)           | -     | (46.4)               | (62.5) | (37.5)            | (67.9)                |

M: male; F: female; OB: obesity; DM: type 2 diabetes mellitus; DL: dyslipidemia; HT: hypertension; LC: liver cirrhosis; Non-LC: non-liver cirrhosis. All values represent number of cases.

- Sasaki et al\[3\] described a 73 year old female with MO of HCC based on cirrhotic NASH. The patient was complicated by T2DM and obesity. Two liver tumors were detected metachronously and both were diagnosed with well-differentiated HCCs.

- The role of each factor in the pathogenesis of MO of HCC is not understood. Old age and cirrhosis have been shown to be the strongest risk factors for the development of HCC in NASH with a prospective cohort study\[37\]. Obesity has been confirmed as an independent risk factor for the development of HCC in several studies\[38­42\], as has T2DM\[43­45\]. With regard to the association of T2DM, it was postulated that chronic hyperinsulinemia and insulin-like growth factor 1 might be involved in carcinogenesis\[46\]. Although MO of HCC may be attributable to independent factors, a concurrence of the factors of old age, metabolic abnormalities and cirrhosis perhaps significantly raises the malignant potential in the liver and probability of subsequent synchronous and multifocal development of HCCs. The exact mechanism of MO of HCC under those conditions needs to be elucidated.

- WJH | www.wjgnet.com

January 27, 2011 | Volume 3 | Issue 1
adapted to cases with metachronous MO because it may not be long enough to observe metachronous MO of HCC in the present study. Even in patients without MO of HCC at diagnosis, HCC of multicentric origin might occur metachronously after longer periods of follow up. Moreover, the number of subjects is too small to draw a clear conclusion. These are limitations of this study and warrant further exploration with a larger scale and longer duration.

Discrimination of MO from IM is critical for selecting an appropriate method of treatment for HCC caused by HCV infection. The prognosis of HCV-related HCC patients with MO is thought to be better than that with IM because of the low rate of recurrence by IM in the MO group. Therefore, it is reasonable to adopt locoregional therapy such as surgical removal or radiofrequency ablation which is more effective than transcatheter arterial chemoembolization or systemic chemotherapy, even in cases with multiple HCCs when they are considered of multicentric origin. However, whether the same strategy can be adapted to NASH-related HCC remains unclear because outcomes of HCC with or without MO in NASH have not been clarified. To establish an adequate strategy against HCC with NASH, their outcomes should be analyzed with stratification on the basis of not only tumor staging, hepatic reserve and kinds of treatment but also the manner of HCC development.

Furthermore, it is important to prevent MO of HCC. In patients with HCV-related HCC, eradication of HCV by interferon therapy after curative treatment for HCC provided promising effects on the prevention of HCC recurrence in several reports. Adjuvant therapy using interferon reduced late recurrence of HCC after two or more years of curative treatment. This fact may be attributable to the suppression of multicentric carcinogenesis through the inhibition of chronic inflammation. Even in NASH, it would be possible that anti-inflammation or anti-fibrosis therapy for the liver leads to the prevention of HCC development with multicentric manner. Based on this, it may be worth attempting to intensely treat underlying liver disease as well as HCC to produce consequent improvement in the prognosis of NASH.

In summary, synchronous and/or metachronous MO was recognized in 4 of 12 patients with NASH-related HCC. MO may be frequently provoked in NASH-related HCC as well as in chronic liver diseases caused by HBV or HCV infection. The clinical status of age older than 70 years, obesity, T2DM, hypertension and cirrhosis was identified as common characteristics of the patients with MO of HCC and they might be predisposing factors to at least synchronous MO. Of these characteristics, old age, T2DM and cirrhosis are also common features of the other 2 patients from the previous case reports so these confined conditions may be necessary preconditions for synchronous MO. Adequate methods of treatment and prevention for MO of HCC are necessary and may lead to a consequent improvement in the prognosis of NASH.

**REFERENCES**

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434–438
2. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80
3. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134–140
4. Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, Shiffman ML, Heuman D, Cotterell A, Fisher RA, Contos MJ, Mills AS. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006; 43: 682-689
5. Yatsuji S, Hashimoto E, Tobari M, Tanai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009; 24: 248-254
6. Zen Y, Katayanagi K, Tsuchiya K, Harada K, Araki I, Nakamura Y. Hepatocellular carcinoma arising in non-alcoholic steatohepatitis. Pathol Int 2001; 51: 127-131
7. Sasaki M, Iatsu K, Minato H, Takamura H, Ohta T, Nakamura Y. Flare-up of nonalcoholic steatohepatitis after hepatectomy resulted in hepatic failure in a patient with type 2 diabetes mellitus. Diag Dis Sci 2007; 52: 3473-3476
8. Takenaka K, Adachi E, Nishizaki T, Hiroshige K, Ikeda T, Tsucheyoshi M, Sugimachi K. Possible multicentric occurrence of hepatocellular carcinoma: a clinicopathological study. Hepatology 1994; 19: 889-894
Kawai H et al. Multicentric occurrence of HCC with NASH

9 Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, Sone Y, Toyoda H, Shimada S, Takahashi M, Sassa T. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997; 25: 87-92

10 Nakashima O, Kojima M. Recurrence of hepatocellular carcinoma: multicentric occurrence or intrahepatic metastasis? A viewpoint in terms of pathology. J Hepatobiliary Pancreat Surg 2001; 8: 404-409

11 Matsumoto Y, Fuji H, Matsuura M, Kono H. Multicentric occurrence of hepatocellular carcinoma: diagnosis and clinical significance. J Hepatobiliary Pancreat Surg 2001; 8: 435-440

12 Oikawa T, Ojima H, Yamasaki M, Takayama T, Hiroshis S, Sakamoto M. Multistep and multicentric development of hepatocellular carcinoma: histological analysis of 983 resected nodules. J Hepatol 2005; 42: 225-229

13 Shimada M, Hamatsu T, Yamashita Y, Rikinmaru T, Taguchi K, Utsunomyi T, Shirabe K, Sugimachi K. Characteristics of multicentric hepatocellular carcinomas: comparison with intrahepatic metastasis. World J Surg 2001; 25: 991-995

14 Brun ET, Jamney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474

15 Liver Cancer Study Group of Japan. The General Rules for liver cancer. [in Japanese]. 5th ed. Tokyo: Kanehara, 2008: 43

16 Hayashi M, Matsu O, Ueda K, Kawamori Y, Kadoya M, Yoshikawa J, Gabata T, Takashima T, Nonomura A, Nakanuma Y. Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium. AJR 1999; 172: 869-976

17 Takayama K, Muramatsu Y, Mizuguchi Y, Miyoriama N, Ojima H. Imaging of early hepatocellular carcinoma and adenomatous hyperplasia (dysplastic nodules) with dynamic CT and a combination of CT and angiography: experience with resected liver specimens. Interanvirology 2004; 47: 199-208

18 Minagawa M, Iki I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg 2007; 245: 309-319

19 Examination Committee of Criteria for Obesity Disease in Japan; Japan Society for the Study of Obesity. New criteria for ‘obesity disease’. Cnt J 2002; 66: 987-992

20 Tokushige K, Hashimoto E, Yatsui S, Tobari M, Taniwai M, Torii N, Shintori K. Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. J Gastroenterol Hepatol 2010; 45: 960-967

21 Cotrim HP, Paraná R, Braga E, Lyra L. Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history? Am J Gastroenterol 2000; 95: 3018-3019

22 Orikasa H, Ohyama R, Tsuka N, Eyden BP, Yamazaki K. Lipid-rich clear-cell hepatocellular carcinoma arising in nonalcoholic steatohepatitis in a patient with diabetes mellitus. J Submicrosc Cytol Pathol 2001; 33: 195-200

23 Shimada M, Hashimoto E, Taniwai M, Hasegawa K, Okuda H, Hayashi N, Takasaka K, Ludwig J. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002; 37: 154-160

24 Mori S, Yamada T, Sakaia I, Takami T, Sakaguchi E, Kimura T, Kurokawa F, Maeyama S, Okita K. Hepatocellular carcinoma with nonalcoholic steatohepatitis. J Gastroenterol 2004; 39: 391-396

25 Bullock RE, Zaitoun AM, Athil GP, Ryder SD, Beckingham IJ, Lobo DN. Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma. J Hepatol 2004; 41: 685-686

26 Cuadrado A, Orive A, García-Suárez C, Domínguez A, Fernández-Salcanet JG, Crespo J, Poms-Romero F. Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma. Obes Surg 2005; 15: 442-446

27 Sato K, Ueda Y, Ueno K, Okamoto K, Iizuka H, Katsuda S. Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid. Virchows Arch 2005; 457: 996-999

28 Ichikawa T, Yanagi K, Motoyoshi Y, Hamasaki K, Nakao K, Toriyama K, Eguchi K. Two cases of non-alcoholic steatohepatitis with hepatocellular carcinoma without cirrhosis. J Gastroenterol Hepatol 2006; 21: 1865-1866

29 Ikeda H, Suzuki M, Takahashi H, Kobayashi M, Okase N, Moriya H, Koike J, Matayama S, Otsutsumi K, Rob F. Hepatocellular carcinoma with silent and cirrhotic non-alcoholic steatohepatitis, accompanying ectopic liver tissue attached to gallbladder. Pathol Int 2006; 56: 40-45

30 Ha S, Kubo S, Shuto T, Tanaka H, Takemura S, Yamamoto T, Kanazawa A, Ogawa M, Hiroshis K, Wakasa K. Hepatocellular carcinoma arising from nonalcoholic steatohepatitis: report of two cases. Surg Today 2006; 36: 390-394

31 Hashizume H, Sato K, Takagi H, Hirokawa T, Kojima A, Sohara N, Kakizaki S, Mochida Y, Shimura T, Sunose Y, Ohkawa S, Mori M. Primary liver cancers with nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol 2007; 19: 827-834

32 Maeda T, Hashimoto K, Kihara Y, Ikegami T, Ishida T, Aimitsu S, Fujiwara M. Surgically resected hepatocellular carcinomas in patients with non-alcoholic steatohepatitis. Hepatogastroenterology 2008; 55: 1404-1408

33 Kawada N, Imanaka K, Kawauchi T, Taniwai C, Ishihara R, Matsunaga T, Gotoh K, Yamada T, Tomita Y. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol 2009; 44: 1190-1194

34 Malik SM, Gupte PA, de Vera ME, Ahmad J. Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma. Clin Gastroenterol Hepatol 2009; 7: 800-806

35 Chagas AL, Kikuchi LO, Oliveira CP, Vezzozzo DC, Mello ES, Oliveira AC, Cella LC, Herman P, Bachella T, Caldwell SH, Alves VA, Carrilho FJ. Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients? Braz J Med Biol Res 2009; 42: 958-962

36 Takuma Y, Nousu K. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and a literature review. World J Gastroenterol 2010; 16: 1436-1441

37 Hashimoto E, Yatsuji S, Tobari M, Taniwai M, Torii N, Tokushige K, Shiratori K. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol 2009; 44 Suppl 19: 89-95

38 Møller H, Møllemgaard A, Lindvig K, Olsen JH. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 1994; 30A: 344-350

39 Wolk A, Gridley G, Svensson M, Nyren O, McLaughlin JK, Fraumeni JF, Adam HO. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001; 12: 13-21

40 Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638

41 Smanic C, Gridley G, Chow WH, Lubin J, Hoover RN, Fraumeni JF Jr. Obesity and cancer risk among white and black United States veterans. Cancer Causes Control 2004; 15: 35-43

42 Oh SW, Yoon YS, Shin SA. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol 2005; 23: 4742-4754

43 El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-468

44 Regimbeau JM, Colombat M, Mognot P, Durand F, Abdalla E, Degott C, Degos F, Farges O, Belghiti J. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004; 10: 569-573

45 Davila JA, Morgan RO, Shaib Y, McLyngh KA, El-Serag HB.
Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. *Gut* 2005; 54: 533-539

46 **Smedile A**, Bugianesi E. Steatosis and hepatocellular carcinoma risk. *Eur Rev Med Pharmacol Sci* 2005; 9: 291-293

47 **Kubo S**, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, Shiomi S, Tamori A, Oka H, Igawa S, Kuroki T, Kinoshita H. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. *Ann Intern Med* 2001; 134: 963-967

48 **Kubo S**, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. *Br J Surg* 2002; 89: 418-422

49 **Mazzaferro V**, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli G, Tagger A, Colombo M, Bonino F, Majno P, Llovet JM. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. *Hepatology* 2006; 44: 1543-1554

**S- Editor** Zhang HN  **L- Editor** Roemmele A  **E- Editor** Liu N